Literature DB >> 843109

Cell-mediated immunity in rheumatoid arthritis.

A A Andrianakos, J T Sharp, D A Person, M D Lidsky, J Duffy.   

Abstract

Cell-mediated immunity in rheumatoid arthritis (RA) was assessed by skin testing with six antigens in 107 patients, 94 of whom were age, sex, and race-matched with healthy individuals or patients with diseases unrelated to immunological abnormalities. 20% of RA patients were anergic. Impaired cell-mediated immunity in the RA patients was manifested by a decrease in the magnitude of skin reactivity as well as a decrease in the incidence of positive reactions to multiple antigens. Depression in cell-mediated immunity was related to age but not to sex, duration of disease, or disease activity. A slight correlation was found between absolute peripheral lymphocyte counts and the number of positive skin tests, and was confirmed by finding an association between lymphocyte counts and the size of skin reactions. A correlation was also found between lymphocyte counts and disease activity. Four explanations of the observed depression in cell-mediated immunity in RA were considered: (1) a preoccupation of the immune mechanism of the host with cell-mediated immunity reactions related to the pathogenesis of the disease; (2) a depression of cell-mediated immune reactivity by a virus infection; (3) depression of cell-mediated immunity by therapy; and (4) immune complex suppression of cell-mediated immunity. No effect of gold therapy was found. The near universal use of salicylates or other anti-inflammatory drugs did not permit investigation of the effect of these drugs on cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843109      PMCID: PMC1006623          DOI: 10.1136/ard.36.1.13

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Contacttype delayed hypersensitivity in patients with rheumatoid arthritis.

Authors:  W L EPSTEIN; R A JESSAR
Journal:  Arthritis Rheum       Date:  1959-04

3.  Proposed diagnostic criteria for rheumatoid arthritis.

Authors:  G A BENNETT; S COBB; R JACOX; R A JESSAR; M W ROPES
Journal:  Bull Rheum Dis       Date:  1956-12

4.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

5.  Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity.

Authors:  J LANSBURY; D D HAUT
Journal:  Am J Med Sci       Date:  1956-08       Impact factor: 2.378

6.  Tuberculin sensitivity in rheumatoid arthritis.

Authors:  O WASZ-HOCKERT
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1951

7.  Depression of cell-mediated immunity in old age and the immunopathic diseases, lupus erythematosus, chronic hepatitis and rheumatoid arthritis.

Authors:  B H Toh; I C Roberts-Thomson; J D Mathews; S Whittingham; I R Mackay
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

8.  Cell-mediated immunity to synovial antigens in rheumatoid arthritis.

Authors:  P A Bacon; A Cracchiolo; R Bluestone; L S Goldberg
Journal:  Lancet       Date:  1973-09-29       Impact factor: 79.321

9.  Suppression of lymphocyte transformation by aspirin.

Authors:  G Opelz; P I Terasaki; A A Hirata
Journal:  Lancet       Date:  1973-09-01       Impact factor: 79.321

10.  Failure of lymphocyte transformation in response to gamma-globulins in rheumatoid arthritis.

Authors:  J N Kacaki; W E Bullock; J H Vaughan
Journal:  Lancet       Date:  1969-06-28       Impact factor: 79.321

View more
  13 in total

1.  QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy.

Authors:  Anthony S Russell; Luiz Lisboa; Marla F Dos Santos; Deepali Kumar; Atul Humar
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

2.  Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes.

Authors:  L A Runge; R S Pinals; R H Tomar
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

3.  Immunosuppressive macrophages induced by arthropathic peptidoglycan-polysaccharide polymers from bacterial cell walls.

Authors:  D R Regan; P L Cohen; W J Cromartie; J H Schwab
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

4.  Cell-mediated immunity in systemic lupus erythematosus.

Authors:  A A Andrianakos; P N Tsichlis; E G Merikas; S G Marketos; J T Sharp; G E Merikas
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

5.  Activation pathways of synovial T lymphocytes. Expression and function of the UM4D4/CDw60 antigen.

Authors:  D A Fox; J A Millard; L Kan; W S Zeldes; W Davis; J Higgs; F Emmrich; R W Kinne
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition.

Authors:  P Emery; G Panayi; D Symmons; G Brown
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

7.  Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy.

Authors:  M G Helliwell; G S Panayi; A Unger
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

8.  Nutritional status in patients with rheumatoid arthritis.

Authors:  M Helliwell; E J Coombes; B J Moody; G F Batstone; J C Robertson
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

9.  Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy.

Authors:  M D Smith; A Smith; J O'Donnell; M J Ahern; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

10.  Possible disease-modifying effects of naproxen in the adjuvant-arthritic rat.

Authors:  N R Ackerman; K Kappas; P Maloney
Journal:  Agents Actions       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.